Moderna Stock On Fire: Up 13% With 5-Day Winning Streak
Moderna (MRNA) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 13% return. The company has gained about $1.2 Bil in value over the last 5 days, with its current market capitalization at about $10 Bil. The stock remains 35.8% below its value at the end of 2024. This compares with year-to-date returns of 16.5% for the S&P 500.
Moderna’s recent streak was fueled by a surprise Q3 earnings beat, with EPS of -$0.51 significantly topping estimates, alongside robust cost-cutting initiatives. This financial discipline and strategic pipeline focus outweighed declining COVID-19 vaccine sales, signaling renewed investor confidence in its evolving mRNA platform.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are several things to fear in MRNA stock given its overall Weak operating performance and financial condition. This isn’t appropriately reflected in the stock’s Moderate valuation which is why we think it is Unattractive (see Buy or Sell MRNA). Nevertheless, stock picking can fail no matter how good the strategy is. High Quality Portfolio turns single-stock insights into a robust market beating portfolio strategy.
For quick background, MRNA develops mRNA-based therapeutics and vaccines for infectious diseases, immuno-oncology, rare, cardiovascular, and auto-immune diseases, with 44 programs including 26 clinical trials across seven modalities.
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
Comparing MRNA Stock Returns With The S&P 500
The following table summarizes the return for MRNA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MRNA | S&P 500 |
|---|---|---|
| 1D | 1.1% | 0.1% |
| 5D (Current Streak) | 13.4% | 0.8% |
| 1M (21D) | 1.8% | 3.1% |
| 3M (63D) | 0.1% | 5.9% |
| YTD 2025 | -35.8% | 16.5% |
| 2024 | -58.2% | 23.3% |
| 2023 | -44.6% | 24.2% |
| 2022 | -29.3% | -19.4% |
However, big gains can follow sharp reversals – but how has MRNA behaved after prior drops? See MRNA Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 113 S&P constituents with 3 days or more of consecutive gains and 13.0 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 30 | 13 |
| 4D | 47 | 0 |
| 5D | 17 | 0 |
| 6D | 11 | 0 |
| 7D or more | 8 | 0 |
| Total >=3 D | 113 | 13 |
Key Financials for Moderna (MRNA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $6.8 Bil | $3.2 Bil |
| Operating Income | $-4.2 Bil | $-3.9 Bil |
| Net Income | $-4.7 Bil | $-3.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $137.0 Mil | $1.0 Bil |
| Operating Income | $-907.0 Mil | $-260.0 Mil |
| Net Income | $-825.0 Mil | $-200.0 Mil |
While MRNA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.